Skip to main content
KLYG
OTC Life Sciences

Kelyniam Swings to Operating Profit as Nine-Month Revenue Jumps 35%

Tom Rudovsky · Reported by ACCESS Newswire
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.1
Mkt Cap
$5.012M
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Kelyniam reported nine-month 2026 revenue of $2,954,087, up 35% from $2,186,491 a year earlier, with gross profit up 41% to $2,383,632. The company swung to operating income of $244,509 from a prior-year operating loss of $(162,373) — its first return to profitability in the period. Management credits the Fusion BCP-PEEK implant launch and CustomizedBone unit sales that more than doubled year over year. For a micro-cap trading near $0.10, a swing to operating profit on roughly $3M of nine-month revenue is a meaningful fundamental shift, though the figures are unaudited and the full Q3 detail, including cash flow, is only posted on the company's website rather than filed with a full financial statement. Watch whether the operating profit holds in Q4 and whether the Fusion launch sustains the unit growth.

At the time of this announcement, KLYG was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $5M. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.


Price Chart

Share this article

Copied!

KLYG - Latest Insights

KLYG
May 11, 2026, 12:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.100
Real-time Price: $0.10495 info
Change: +$0.00495 (+5%) info
Market Cap: $5.26M info